Filter by business model, region, score band and the documents each supplier publishes.
Loading directory…
RK Pharma subsidiary offering API process R&D, custom synthesis and generic APIs, with US offices and plants in Gujarat and Andhra Pradesh. Holds US DMFs for 6 peptide APIs.
Aspen Pharmacare's API site in Oss, Netherlands, with roots in 1923; makes peptides with a liquid-phase process plus hormones and heparin. Holds US DMFs for 4 peptide APIs.
Tianjin unit of Asymchem, a CDMO listed in Shenzhen and Hong Kong that makes peptides and oligos; US DMFs for liraglutide and semaglutide.
Peptide API subsidiary of Aurobindo Pharma with a plant near Hyderabad. Makes generic peptide APIs and runs GMP contract projects from mg to kg scale.
Privately owned Barcelona peptide CDMO founded in 1989, making GMP generic peptide APIs and custom NCE peptides. Holds US DMFs for 10 peptide APIs.
Hangzhou peptide CRDMO founded in 2001, part of CPC Scientific/Medtide, with production in China and the USA. Holds US DMFs for cetrorelix, semaglutide and tirzepatide.
Taiwanese API maker founded in 1964, trading as Cenra API Solutions, offering CMO/CDMO services. Holds US DMFs for difelikefalin, plecanatide and setmelanotide.
Hyderabad injectables CDMO founded 1978, promoted by Fosun Pharma; FDA-inspected sites; US DMF for glatiramer acetate.
Gwangju peptide API maker founded in 2000 as Anygen, KOSDAQ-listed since 2016, with MFDS-approved GMP peptide plants; holds US DMFs for ganirelix and vasopressin.
Riga drug maker operating since 1946 that now offers CDMO services; WHO-inspected oxytocin API site; US DMF for oxytocin.
Hyderabad-based MSN Group entity holding US DMFs for 11 peptide APIs, including semaglutide and tirzepatide. MSN runs 27 plants in India, the USA and Indonesia.
Indian CDMO whose Turbhe, Navi Mumbai site develops and makes peptide APIs by solid- and solution-phase synthesis. Holds US DMFs for 9 peptide APIs.
Hamburg microbial biologics CDMO founded 1987, now wholly owned by Gedeon Richter; FDA-inspected 2013, 2018 and 2026; US DMF for teriparatide.
Raichur API and CDMO subsidiary of Shilpa Medicare; US DMFs for desmopressin, liraglutide and octreotide; Raichur units inspected by US FDA in 2025.
Neijiang, Sichuan injectables and API maker founded in 2010, listed on Shanghai's STAR Market, with FDA and UK MHRA GMP inspections; holds an active US DMF for lanreotide.
Jiangsu peptide CDMO and generic API supplier with large automated SPPS capacity; states it has passed four US FDA inspections. Holds US DMFs for 9 peptide APIs.
Dutch holding entity of TAPI, Teva's API and CDMO business, with peptide development and GMP production across a global plant network. Holds US DMFs for 9 peptide APIs.
Privately held CDMO with peptide synthesis from discovery to commercial scale.
US peptide API CDMO with facilities in the US and China.
Swiss peptide and oligonucleotide CDMO with GMP plants in Europe and the US.
Greek peptide manufacturer producing GMP and non-GMP peptides and resins.
French API producer spun out of Sanofi. Its Frankfurt site at Hoechst Industrial Park runs a CDMO platform for peptide and oligonucleotide development and cGMP manufacture.
Peptide, HPAPI and bioconjugate manufacturing within Lonza's small-molecule business.
Indian API manufacturer and CDMO with a peptide synthesis platform.
Peptide-focused CDMO running GMP manufacturing sites on three continents.
API manufacturer and CDMO focused on complex generics, including peptides.
Privately owned Swiss CDMO near Zurich, in business since 1963, that makes peptide APIs, peptide fragments and amino acid derivatives by solid- and solution-phase synthesis.
Peptide and oligonucleotide CRDMO unit of WuXi AppTec, covering discovery through API and drug product manufacture. WuXi STA's peptide projects are routed to this platform.
Ajinomoto group CDMO for small molecules, oligonucleotides, peptides and biologics. It makes GMP peptides with its AJIPHASE liquid-phase process at sites in Belgium and Japan.
California peptide synthesizer maker founded 1993 that also runs a cGMP peptide CDMO site in Milpitas; US DMF for triptorelin.
Chongqing API maker founded in 2016 covering high-potency APIs, peptides and XDC compounds with CDMO services; reports FDA on-site inspections in 2024 and 2025 and holds a US DMF for semaglutide.
European CDMO network with a dedicated peptide, lipid and carbohydrate platform.
Fresenius Kabi's Italian API unit; its Villadose site near Venice develops and makes peptide APIs, also offered through Fresenius Kabi contract manufacturing. Holds US DMFs for 6 peptide APIs.
Mumbai peptide API maker acquired by Piramal Pharma in 2021; its oxytocin API is WHO-prequalified; US DMF for oxytocin.
Shanghai recombinant protein and enzyme maker, listed on the STAR Market, offering CMC development and GMP manufacturing; holds a US DMF for a semaglutide peptide fragment.
Austrian CDMO for GMP peptide APIs at milligram to hectogram scale.
Chinese end-to-end CDMO with a peptide and oligonucleotide (TIDES) platform. It runs manufacturing sites in China and in New Jersey, USA.
Indian contract research, development and manufacturing organization (CRDMO) listed on NSE and BSE. It has opened a dedicated Peptide Research Center in Hyderabad.
Shenzhen peptide CDMO and API maker founded in 2009, with 13 cGMP lines and 85,000 L of SPPS/LPPS reactor volume. Holds US DMFs for 6 peptide APIs.
API CDMO with sites in the UK, Ireland and the US. Its Cork, Ireland facility focuses on peptide manufacturing and large-scale chromatography.
Suzhou API and intermediate maker founded in 2000 offering CDMO/CMO services; holds an active US DMF for semaglutide.
Suzhou peptide API and formulation maker founded in 2000, flagship of Tianma Pharma Group, offering CRO/CMO/CDMO services. Holds US DMFs for 8 peptide APIs.
Zunyi, Guizhou peptide manufacturer offering development and kg-scale production; holds active US DMFs for tirzepatide and other peptides.
Hangzhou peptide and oligonucleotide CRDMO supporting projects from preclinical to commercial supply; holds active US DMFs for tirzepatide and inclisiran.
Hangzhou peptide maker founded in 2014 offering pharmaceutical, cosmetic and catalog peptides plus peptide CRO/CDMO work; holds an active US DMF for semaglutide.
Hangzhou peptide developer offering peptide APIs, intermediates, impurities and ADC/PDC linkers plus custom synthesis and process development; holds an active US DMF for tirzepatide.
Hangzhou peptide API maker and CDMO founded in 2019, supplying therapeutic and cosmetic peptides. Holds US DMFs for linaclotide, semaglutide and tirzepatide.
Ningxia API and peptide maker founded in 2016 in Pingluo, offering peptide API development and manufacturing; holds US DMFs for semaglutide and tirzepatide.
Japanese CDMO set up in 2017 to develop and manufacture special peptide and oligonucleotide APIs, from milligram samples to multi-kilogram GMP batches.
Suzhou peptide CRDMO with GMP workshops built to ICH Q7; US DMFs for semaglutide and tirzepatide.
Suzhou API and intermediates producer offering customized manufacturing. Holds US DMFs for semaglutide, thymalfasin and tirzepatide.
Wuhan fermentation-based CDMO founded 2008 making GLP-1 APIs, proteases and cell products; US DMFs for semaglutide and its main chain.
Nantong company founded in 2020 that makes peptides by biosynthesis and offers peptide CMC development. Holds US DMFs for semaglutide and tirzepatide.